<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="142782">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01698684</url>
  </required_header>
  <id_info>
    <org_study_id>TA-501</org_study_id>
    <nct_id>NCT01698684</nct_id>
  </id_info>
  <brief_title>Research Evaluating a PDE5 Inhibitor for Erectile Dysfunction</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Evaluation of Avanafil for On-Demand Treatment of Men With Erectile Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VIVUS, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VIVUS, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to examine the therapeutic effects of two doses of avanafil
      after dosing in men with erectile dysfunction
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in percentage of sexual attempts in which subjects are able to maintain an erection of sufficient duration to have successful intercourse</measure>
    <time_frame>Week 0 (Baseline), Week 8 (End of Study)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">440</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Avanafil 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Avanafil 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One dose 15 minutes before attempting intercourse</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avanafil 100 mg</intervention_name>
    <description>One dose 15 minutes before attempting intercourse</description>
    <arm_group_label>Avanafil 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avanafil 200 mg</intervention_name>
    <description>One dose 15 minutes before attempting intercourse</description>
    <arm_group_label>Avanafil 200 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males â‰¥ 18 years of age;

          -  Minimum 6 months of erectile dysfunction;

          -  In a monogamous, heterosexual relationship for at least 3 months;

          -  Agree to make at least 4 attempts at intercourse per month;

          -  Provide written informed consent;

          -  Agree not to use any other ED treatments for erectile dysfunction;

          -  Willing and able to comply with all study requirements.

        Exclusion Criteria:

          -  Allergy or hypersensitivity to PDE5 inhibitors;

          -  History of dose-limiting AEs with a PDE5 inhibitor or discontinued use of a PDE5
             inhibitor;

          -  Concomitant use of one or more of the following medications:

               -  Other prescription or OTC drugs known to interfere with metabolism by the CYP
                  3A4 enzyme;

               -  Dose of an alpha blocker that has not been stable for at least 14 days;

               -  Any nitrate;

          -  ED as a consequence of advanced neurologic disease, spinal cord injury,or radical
             prostatectomy;

          -  Myocardial infarction, stroke, life-threatening arrhythmia or coronary
             revascularization within the past 6 months;

          -  Unstable angina, angina with sexual intercourse, or congestive heart failure &gt; NYHA
             Class II;

          -  Poorly controlled type 1 or type 2 diabetes;

          -  Evidence of prostate cancer or previous radical prostatectomy;

          -  Untreated hypogonadism or total testosterone levels outside normal reference range;

          -  Abnormal laboratory value(s) judged to be clinically significant by the investigator;

          -  Positive urine drug screen;

          -  History of retinitis pigmentosa, nonarteritic anterior ischemic optic neuropathy or
             glaucoma;

          -  Previous participation in any other study with avanafil;

          -  Use of any other investigational medication or device for any indication within 30
             days prior to enrollment or at any time during this study;

          -  Evidence of any clinically significant medical, psychiatric, social or other
             condition by history, physical examination or laboratory studies that, in the opinion
             of the investigator, would contraindicate the administration of study medications,
             affect compliance, interfere with study evaluations, limit study participation,
             contraindicate sexual activity or confound the interpretation of study results.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chuck Bowden, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>VIVUS, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 13, 2014</lastchanged_date>
  <firstreceived_date>September 25, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ED</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Phosphodiesterase 5 Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
